Regulatory Intelligence: What the Rules Actually Require
Regulation determines what can be sold, what can be claimed and what has been verified, and the answers differ enough by jurisdiction to change what is available.
The Short Answer
Regulatory frameworks explain several things that otherwise look arbitrary: why a compound is available in one country and not another, why claims are worded so carefully, why nobody verified a product before it went on sale, and why a supplement can be withdrawn years after a problem emerged. None of it is a proxy for evidence, and understanding it prevents both false reassurance and false alarm.
The United States Framework
Dietary supplements are regulated under a framework established in 1994 which places them in a category distinct from both foods and drugs.
No pre-market approval for safety or efficacy is required for ingredients marketed before that date. New dietary ingredients require notification with safety information rather than approval.
Manufacturers are responsible for ensuring products are safe and labels are accurate. Enforcement is post-market, which means action follows a problem rather than preventing it.
Good Manufacturing Practice requirements apply, covering identity, purity, strength and composition, with inspection coverage limited relative to the number of facilities.
Claims are constrained. Structure and function claims, describing an effect on a body structure or function, are permitted with a disclaimer stating the claim has not been evaluated by the regulator. Disease claims, stating a product treats or prevents a disease, require drug approval. This is why supplement marketing uses the phrasing it does.
The category two bulk substances list identifies substances not eligible for compounding, which is the mechanism that removed BPC-157 from legitimate compounding pharmacy supply.
The investigated-as-a-drug exclusion is why NMN's status changed: a substance investigated as a drug before being marketed as a supplement can be excluded from the supplement category, which is a legal rather than safety distinction.
The European Framework
| Element | Approach |
|---|---|
| Category | Food supplements, regulated as foods |
| Health claims | Only claims on an authorised list may be made; the assessment bar is high |
| Novel foods | Ingredients without significant pre-1997 consumption history require authorisation |
| Maximum levels | Set for some vitamins and minerals, with variation between member states |
| Botanicals | Handled inconsistently across member states; some are medicines in one country and supplements in another |
| Borderline products | National authorities classify case by case, producing genuine cross-border differences |
The authorised health claims list is the most consequential difference from the US approach. Claims are assessed for scientific substantiation before being permitted, and a large majority of submitted claims have been rejected. The practical effect is that European supplement labelling is more restrained, and the absence of a claim does not indicate absence of effect, only that no authorised claim exists.
The botanical inconsistency explains a common confusion: the same plant extract can be a licensed herbal medicine in one member state, a food supplement in another, and unavailable in a third.
Other Jurisdictions Worth Knowing
Australia. Complementary medicines are listed or registered with the therapeutic goods regulator. Listed products use permitted ingredients and indications with sponsor certification; registered products undergo assessment. This imposes more pre-market structure than the US framework.
Canada. Natural health products require a product licence with a product number, involving assessment of safety, efficacy and quality against the claim made.
Japan. Foods with function claims and foods for specified health uses operate under systems with differing evidence requirements, the latter involving government review.
United Kingdom. Post-transition, broadly similar to the European approach with its own authorised claims register and traditional herbal registration scheme.
The practical implications for a consumer: availability differs, so a compound may be legitimately purchasable in one country and not another; claims differ, so the same product carries different labelling; and cross-border online purchase means a product may not comply with the rules where it is used, and imported products may not have been assessed under any framework.
None of this indicates quality directly. A product legal in a permissive jurisdiction may be excellent, and one from a strict jurisdiction may be poorly formulated.
What Regulation Does Not Tell You
Three misreadings are common and worth stating explicitly.
Legal availability is not evidence of efficacy. Most supplements are legally sold without any demonstration that they work, which is the design of the framework rather than a failure of it.
Absence of an authorised claim is not evidence of no effect. A claim may be unauthorised because nobody submitted it, because the dossier was inadequate, or because the effect is real but not demonstrated to the required standard.
A regulatory action is not always a safety finding. NMN's exclusion from the US supplement category was a legal consequence of prior drug investigation, not a safety determination. Conversely, BPC-157's category listing did cite insufficient safety information.
Two further points matter for interpretation. Adverse event surveillance for supplements is considerably weaker than for medicines, with no systematic post-market monitoring in most jurisdictions, so absence of reported harm is weak evidence of safety. And enforcement is resource-limited, so the existence of a rule does not mean compliance is verified.
The 1989 tryptophan contamination episode remains the reference case: thousands of cases of eosinophilia-myalgia syndrome and dozens of deaths, detected through clinical surveillance rather than any supplement monitoring system, and a significant influence on the framework that followed.
Where Regulation Genuinely Helps
It identifies what has been assessed. A Canadian product number or an Australian listing indicates a framework was applied, which is information a US supplement facts panel does not convey.
It constrains the worst claims. Disease claims requiring drug approval prevents supplements being marketed as therapies, which is a meaningful protection.
Authorised claims lists are a usable evidence filter. The European authorised claims that survived assessment are, in effect, a short list of substantiated nutrient effects, and it is a conservative and useful reference.
Safety communications and category listings flag specific hazards, and following them is worthwhile.
Recalls and enforcement actions identify adulterated products, and the categories where they cluster, sports, weight loss and sexual performance products, are worth avoiding.
Banned substance frameworks in sport create a certification market that produces genuinely better-verified products, which benefits non-athletes buying them too.
The practical use: check whether a compound has a regulatory action against it, note whether a product carries an assessment marker in a jurisdiction that requires one, and use authorised claims lists as a conservative evidence reference rather than as the whole picture.
What This Means Practically
Do not read availability as endorsement. Legal sale means the framework permits it, not that it works.
Do not read cautious labelling as weakness. A European product with no health claim may be identical to a US product making several.
Check for regulatory actions on anything unusual, particularly peptides, novel compounds and anything sold as a research chemical.
Be cautious with cross-border purchases, since an imported product may not have been assessed under any framework and may not comply where you are.
Prefer jurisdictions with pre-market assessment where a choice exists, as one input among several.
Keep certification separate from regulation. Third-party testing verifies content and purity, regulation governs what can be sold and claimed, and neither verifies efficacy.
Understand that a category change may not be about safety. When a compound becomes unavailable, read the actual reason rather than assuming either a safety finding or a commercial conspiracy.
Regulation is a floor rather than a recommendation. Knowing where the floor is prevents mistaking it for a ceiling.
The AEONNN Perspective
The Regulatory layer answers questions the Evidence layer cannot: what is legally available, what may be claimed, and what has been assessed by anyone before sale. Those are separate from whether something works, and conflating them produces both false reassurance and false alarm.
Two distinctions AEONNN keeps explicit. A regulatory action is not always a safety finding: NMN's exclusion from the US supplement category followed prior drug investigation, a legal consequence, while BPC-157's category listing did cite insufficient safety information. And absence of an authorised health claim in Europe does not mean absence of effect, only that no claim survived assessment.
Where the layer genuinely helps is in three places. Regulatory actions and category listings flag specific hazards worth honouring. Authorised claims lists function as a conservative evidence filter, since a large majority of submitted claims were rejected. And banned-substance certification for sport has produced a market of better-verified products that benefits everyone buying them. The platform's underlying position is that regulation is a floor rather than a recommendation, and that surveillance for supplement adverse events is weak enough that absence of reported harm is weak evidence of safety.
Pillar Matrix mapping
Database Matrix layers
- Regulatory Layer (EFSA, FDA, EMA)
- Safety Layer (DrugBank, FAERS)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
Do supplements need approval before sale?
In the United States, generally no, for ingredients marketed before 1994; new dietary ingredients require notification rather than approval. Australia and Canada impose more pre-market structure.
Why is supplement labelling worded so carefully?
Structure and function claims are permitted with a disclaimer, while disease claims stating a product treats or prevents a disease require drug approval. That constraint shapes the language.
Why are European labels so restrained?
Only claims on an authorised list may be made, the assessment bar is high, and a large majority of submitted claims have been rejected.
Does no authorised claim mean no effect?
No. A claim may be unauthorised because nobody submitted it, because the dossier was inadequate, or because the effect is real but not demonstrated to the required standard.
Why did NMN become hard to buy in the US?
Because a substance investigated as a drug before being marketed as a supplement can be excluded from the supplement category. That is a legal distinction rather than a safety finding.
Is legal availability a sign a supplement works?
No. Most supplements are legally sold without any demonstration of efficacy, which is how the framework is designed.
Does absence of reported harm mean a supplement is safe?
Weakly at best. Adverse event surveillance for supplements is considerably weaker than for medicines, with no systematic post-market monitoring in most jurisdictions.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.